Opendata, web and dolomites

ONCO-VAX SIGNED

A multifaceted cancer immunotherapy based on an immune checkpoint-modulating chimeric oncolytic virus vector in combination with a dendritic cell vaccine

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 ONCO-VAX project word cloud

Explore the words cloud of the ONCO-VAX project. It provides you a very rough idea of what is the project "ONCO-VAX" about.

disappointing    disease    malignancy    burden    patient    immuno    potentially    dendritic    imposes    immunotherapy    optimized    treat    liver    ovs    virus    directed    mass    lysis    medical    financially    carcinoma    dramatic    worldwide    epidemiologically    systemic    combat    hepatocellular    transforming    reaching    viruses    employ    monotherapeutics    oncology    broad    backbone    vaccine    societal    multimodal    limited    synergistic    antitumor    edge    subset    onco    platform    immune    treating    restricts    local    intratumoral    chimeric    suppressive    despite    health    direct    stimulating    successful    express    enhanced    spread    decades    initiate    replication    utilized    eradicating    mechanism    cancer    cutting    elegant    basis    scheme    therapeutic    gene    nevertheless    metastatic    therapy    multifaceted    cell    capacity    stimulatory    solid    inherently    layer    tumors    heavy    ov    intensive    spreading    antiviral    innate    combination    hcc    strategy    patients    additional    shift    combined    immunity    life    vax    microenvironment    tumor    oncolytic    paradigm    innovative   

Project "ONCO-VAX" data sheet

The following table provides information about the project.

Coordinator
KLINIKUM RECHTS DER ISAR DER TECHNISCHEN UNIVERSITAT MUNCHEN 

Organization address
address: ISMANINGER STRASSE 22
city: MUENCHEN
postcode: 81675
website: http://www.med.tu.muenchen.de

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Germany [DE]
 Total cost 1˙499˙988 €
 EC max contribution 1˙499˙988 € (100%)
 Programme 1. H2020-EU.1.1. (EXCELLENT SCIENCE - European Research Council (ERC))
 Code Call ERC-2019-STG
 Funding Scheme ERC-STG
 Starting year 2020
 Duration (year-month-day) from 2020-04-01   to  2025-03-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    KLINIKUM RECHTS DER ISAR DER TECHNISCHEN UNIVERSITAT MUNCHEN DE (MUENCHEN) coordinator 1˙499˙988.00

Map

 Project objective

Despite many decades of intensive research, cancer remains a major worldwide health concern and imposes a heavy societal burden, both epidemiologically and financially. Cancer immunotherapy is rapidly transforming the face of medical oncology as an exciting paradigm shift in treating cancer by exploiting the immune system of the patient as the basis for the therapy. Although dramatic results have been achieved in a subset of patients, the responses in most solid tumors have been disappointing. Hepatocellular carcinoma (HCC) represents a particularly challenging malignancy to treat, due to the inherently immune-suppressive microenvironment in the liver. Oncolytic viruses (OVs) offer an elegant multimodal approach to combat HCC through their ability to cause direct tumor cell lysis, while stimulating immune responses directed against the tumor. Nevertheless, the potential of OVs as monotherapeutics is limited by the innate antiviral immune response, which rapidly restricts virus replication and spread within the tumor mass. Therefore, a successful therapeutic strategy should employ a combination scheme involving a mechanism to improve the intratumoral dissemination of the OV, while exploiting the immune-stimulatory capacity of the virus, in order to achieve far-reaching synergistic responses that can target metastatic disease. The ONCO-VAX approach aims to accomplish just that. A novel chimeric oncolytic virus backbone with an enhanced cell-cell spreading capacity, will be utilized as a platform to express an optimized gene for eradicating the local immune-suppressive microenvironment in the tumor. As an additional layer of therapy, the virus will be combined with a cutting edge dendritic cell vaccine approach to initiate a broad antitumor response for systemic and potentially life-long immunity against the cancer. This multifaceted approach represents an innovative and crucial step forward in the rapidly evolving field of cancer immuno-oncology.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "ONCO-VAX" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "ONCO-VAX" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.1.)

FatVirtualBiopsy (2020)

MRI toolkit for in vivo fat virtual biopsy

Read More  

FLATBANDS (2020)

Exploring strong correlations in flat bands

Read More  

AUTOMATION (2018)

AUTOMATION AND INCOME DISTRIBUTION: A QUANTITATIVE ASSESSMENT

Read More